Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM), the best-performing biotech of the year, were ripping higher Monday following a positive clinical readout.

High Flying Biotech Axsome Skyrockets On Positive Late-Stage Results For Depression Drug

Shares of Axsome Therapeutics AXSM, -3.66% rocketed 82% in premarket trading on Monday after the biopharma company said its experimental treatment for depression met the primary endpoint in a Phase 3 clinical trial.

Axsome shares jump on positive findings for depression drug

Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint)

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder

A Last-Minute Look At AXS-05 Revealed That Axsome Therapeutics May Have A Better Risk/Reward Profile In Its Major Depressive Disorder Pipeline

Akcea Therapeutics

AMAG Pharmaceuticals

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

Axsome Therapeutics Inc (NASDAQ: AXSM) shares advanced strongly Tuesday after the company reported a positive mid-stage readout for its investigational compound to treat narcolepsy.

This Biotech Is On Track To End 2019 As The Best Performing Stock In The Sector

The company's late-stage pipeline just got a little bigger.

Here's Why Axsome Therapeutics Is on the Move Today

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares jumped early on Tuesday after the firm announced positive results from its midstage narcolepsy trial.

Why Investors Shouldn’t Sleep on This Narcolepsy Study

Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

AbbVie

Vertex Pharmaceuticals

These biotech stocks cover all the bases, from great dividends to promising pipelines.

3 Top Biotech Stocks to Buy in December

Ares Commercial Real Estate

Digital Turbine

Cannae Hlds

Constellation Pharmaceuticals Inc

California Resources

Carrizo Oil & Gas

Signet Jewelers

Southwestern Energy

These are the small cap stocks with the best value, fastest growth, and most momentum for November.

Top Small Cap Stocks for November 2019

Kodiak Sciences Inc

Krystal Biotech

Despite soaring already, these biotech stocks aren't finished climbing.

3 Biotech Stock Rockets With More Fuel in the Tank

The company encountered a delay for its most important clinical trial, but still expects six data readouts for three pipeline assets in the next seven months.

Axsome Therapeutics Shakes Off Post-Earnings Tumble, With Data Barrage on the Way

Axsome Therapeutics: AXS-07 And AXS-12 Approval Potential Should Aid In Its Valuation

Axsome Therapeutics, Inc (AXSM) CEO Herriot Tabuteau on Q3 2019 Results - Earnings Call Transcript

The company encountered a delay in an important clinical trial, but it will lead to better outcomes for patients in the long run.

Here's Why Axsome Therapeutics Fell as Much as 20.5% Today

Axsome Therapeutics' AXS-05 Has Potential To Become A First-Line Treatment For Depression

There's a pair of gems hiding in plain sight.

2 Under-the-Radar Biotech Stocks That Could Make You Rich

Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine

Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine

Enrollment in MOMENTUM Phase 3 migraine trial of AXS-07 in patients with history of inadequate response nearly complete; on track for topline results in 4Q 2019

Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine

NEW YORK, Oct.  21, 2019  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the CONCERT study, a Phase 2, randomized, double-blind, placebo-controlled, crossover, trial of AXS-12 in patients with narcolepsy. AXS-12 (reboxetine) is a novel, oral, potent and highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. Axsome remains on track to report topline results from CONCERT in the fourth quarter of 2019.

Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy

NEW YORK, Oct.  16, 2019  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the GEMINI study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in patients with major depressive disorder (MDD). AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. Axsome remains on track to report topline results from GEMINI in the fourth quarter of 2019.

Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

Axsome Therapeutics is scheduled to release the topline data from four clinical trials this year.

Axsome Therapeutics: Sizable Sales Upside From A Promising Trial Demands A Premium

Bausch Health Companies Inc

Change Healthcare Inc

HealthEquity

La Jolla Pharmaceutical

This year, for the first time in many years, active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

News for Axsome Therapeutics Stock (AXSM)